The Global Primary Biliary Cholangitis Treatment Market
, by Treatment Type (Ursodeoxycholic acid (UDCA), and Obeticholic acid (Ocaliva)), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), the market was valued at US$ 526.4 million
in 2017, and is projected to exhibit a CAGR of 36.3%,
during the forecast period (2018 - 2026), as highlighted in a new report published by .
Increasing pipeline studies to develop prominent treatments for rare diseases such as primary biliary cholangitis are expected to boost the primary biliary cholangitis treatment market growth. For instance, in August 2017, Zydus Discovery DMCC, initiated phase 2 clinical trial for Saroglitazar magnesium 2 mg. The aim of the study was to evaluate safety, tolerability, and efficacy of Saroglitazar Magnesium in patients with primary biliary cholangitis (EPICS).The study is estimated to complete in March 2019.
Browse 20 Market Data Tables and 17 Figures spread through 143 Pages and in-depth TOC on "Primary Biliary Cholangitis Treatment Market, by Treatment Type by Treatment Type (Ursodeoxycholic acid (UDCA), and Obeticholic acid (Ocaliva)), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Forecast to 2026"
To know the latest trends and insights related to Primary Biliary Cholangitis Treatment market, click the link below:
Manufacturers are engaged in developing therapeutic treatment for the patients with primary biliary cholangitis, which in turn is expected to drive the primary biliary cholangitis treatment market size. For instance, in March 2015, NGM Biopharmaceuticals, Inc., announced the positive results for phase 2 trial of NGM282 in patients with Primary Biliary Cirrhosis (PBC). NGM282 is an engineered protein variant of human hormone, fibroblast growth factor 19 (FGF19) that maintains bile acid and metabolic regulatory activities as well as eliminates tumorigenic effects of FGF-19. According to the study results, NGM282 is proven to be a potent regulator of bile acid synthesis.
Furthermore, in June 2016, Retrophin Inc. acquired ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC. Ursodeoxycholic acid is a naturally occurring bile acid that dissolves gall bladder stone rich in cholesterol and also improves the flow of bile in primary biliary cholangitis. Moreover, in February 2018, Intercept Pharmaceuticals, Inc. announced the updated prescribing information for Ocaliva (obeticholic acid or OCA) in the U.S. to emphasize appropriate dosing in primary biliary cholangitis (PBC) patients with Child-Pugh Class B or C or decompensated cirrhosis.
However, lack of awareness among the patients, families and physicians, which result into delayed diagnosis for rare diseases, may hinder primary biliary cholangitis treatment market growth. Most of symptoms associated with rare diseases are masked by the symptoms of common illness and may not be detected by doctors.
Key Takeaways of the Primary Biliary Cholangitis Treatment Market:
- The global primary biliary cholangitis treatment market is expected to expand at a CAGR of 36.3% during the forecast period (2018 – 2026), owing to increasing initiatives by the key player to develop prominent treatment options for the treatment of PBC.
- Increasing prevalence of PBC in the U.S. is expected to drive growth of the market. For instance, as per National Center for Biotechnology Information (NCBI) data, the prevalence of PBC from 2006 through 2016, increased from 21.7 to 39.2 per 100,000 persons in the U.S.
- Major players operating in the global primary biliary cholangitis treatment market include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Retrophin, Inc., Calliditas Therapeutics AB, and GlaxoSmithKline (GSK) pharmaceuticals.